ERBB2 and breast carcinoma: Moreover, the ROR score has been reported to add more prognostic information than the clinical treatment score, recurrence score (Oncotype Dx) and IHC-4 in both node-negative and node-positive, HER-2 negative early breast cancer [9, 12].